

Vetbiobank confirms its leading position in veterinary regenerative medicine by obtaining for its new facility the first authorization issued in France for manufacturing veterinary cell-based therapy.

Since 2011 Vetbiobank has brought to light the potential of neonatal mesenchymal stem cells to successfully treat animal chronic inflammatory diseases.

In just a few years, we have been able to demonstrate to:

- The scientific and veterinary community, the remarkable long-term efficacy of our neonatal stem cells for chronic inflammatory conditions (Cabon et al, Frontiers Vet Science 2019; Taroni et al, Frontiers Vet Sci. 2017).
- Horse and dog's owners that our products are produced through an ethical process using stem cells collected at birth, therefore respecting completely animal welfare (i.e. without medical or surgical intervention impacted on the donor).
- Industrial partners, the business potential of our product, with an initial contract renewed in May 2019 for the development of canine osteoarthritis treatment.
- Investors the management's ability to deliver value, and in return they showed their faith during the company's 2019 financial round, by contributing more than one million euros.

In addition, the company has expanded into additional new laboratories dedicated to manufacturing at the Innovation Centre managed and administered by Lyonbiopole and obtained a licence from French regulatory agency to operate a veterinary pharmaceutical facility. This is the first authorization granted in France for the manufacture of veterinary cell therapy drugs subject to clinical trials. It recognizes the quality of Vetbiobank's technical and organizational ability to develop safe premium treatment products.

In order to implement its defined strategic action plan, Vetbiobank has strengthened its executive team. "We are pleased to announce the recruitment of Mr Harald Egelhofer (Pharm.D) as Director of Bio-manufacturing. His experience of more than 25 years in the technical and regulatory development of human cell therapies at the Etablissement Français du Sang (French National Blood Service) will ensure the achievement of our industrial and regulatory objectives within the expected timelines." Commented Stéphane Maddens CEO. "I am delighted to be part of the Vetbiobank adventure and to invest my time and expertise to head the biomanufacturing activities in our new pharmaceutical facility," said Harald Egelhofer.

Based on its success, Vetbiobank is confident that it will be able to implement its entire program for the upcoming European market launch of its flagship product for the treatment of canine osteoarthritis. This will provide dog owners access to an affordable, effective and safe one-shot cell-based treatment that will enable man's best friend to regain real mobility and long term quality of life.

Vetbiobank

Vetbiobank, a leader in veterinary regenerative medicine, is the first French laboratory to harness the biological potential of neonatal stem cells to treat our four-legged friends suffering from chronic inflammatory diseases.

Today, primarily osteoarthritis, is one of the major health problems in humans and animals. It affects 1 in 5 dogs and one in 2 competition horses causing severe joint pain that results in a progressive loss of mobility and well-being.

The consequences are also distressing for dog owners who are looking for an alternative to conventional treatments (i.e. anti-inflammatory drugs; visco-supplementation) which involve repeated doses of medicines that are only palliative and often poorly tolerated. This leads to compliance issues and ultimately treatment failure which entails using surgery as a last resort. One shot, regenerative medicine, by contrast ensures safe long term effectiveness fulfilling the needs of dog, owner, and the vet.

Ils nous soutiennent :

